BamSEC and AlphaSense Join Forces
Learn More

REGENXBIO Inc.

NASDAQ: RGNX    
Share price (12/20/24): $7.62    
Market cap (12/20/24): $378 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 12 pages Consulting Agreement
12/34/56
EX-10.1
from 10-Q 10 pages September 14, 2024 Vittal Vasista 1218 Harve Lafitte Drive Austin, Tx 78746 Dear Vit
12/34/56
EX-10.2
from 10-Q 12 pages Agreement
12/34/56
EX-10.1
from 10-Q 10 pages This Employment Agreement (This "Agreement") Is Entered Into and Made Effective as of July 1. 2024, by and Between Curran Simpson (The "Employee") and Regenxbio Inc., a Delaware Corporation (The "Company"). 1. Position
12/34/56
EX-10.9
from 10-K 9 pages This Employment Agreement (This "Agreement") Is Entered Into and Made Effective as of , by and Between (The "Employee") and Regenxbio Inc., a Delaware Corporation (The "Company"). 1. Position
12/34/56
EX-10.1
from 10-Q 2 pages Regenxbio Inc. Compensation Program for Non-Employee Directors
12/34/56
EX-10.1
from 10-Q 9 pages Certain Identified Information Has Been Excluded From This Exhibit Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. [Letterhead of Penn Center for Innovation]
12/34/56
EX-10.40
from 10-K 8 pages Certain Identified Information Has Been Excluded From This Exhibit Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. Settlement Agreement and Mutual Release
12/34/56
EX-10.1
from 10-Q 103 pages Certain Identified Information Has Been Excluded From This Exhibit Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. Collaboration and License Agreement Between Regenxbio Inc. and Abbvie Global Enterprises Ltd. Dated as of September 10, 2021
12/34/56
EX-10.42
from 10-K 54 pages Certain Identified Information Has Been Excluded From This Exhibit Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. Royalty Purchase Agreement Between Regenxbio Inc., as Seller the Entities Set Forth on Schedule 1.1 Hereto, as Purchaser, and Hcr Collateral Management LLC, as Purchaser Representative Dated as of December 22, 2020
12/34/56
EX-10.5
from 10-K 6 pages Regenxbio Inc. 2015 Equity Incentive Plan Notice of Stock Option Grant
12/34/56
EX-10.4
from 10-K 5 pages Regenxbio Inc. 2015 Equity Incentive Plan Notice of Restricted Stock Unit Award
12/34/56
EX-10.4
from 10-Q 3 pages Third Amendment to Lease Agreement
12/34/56
EX-10.3
from 10-Q 10 pages Fifth Amendment to Lease
12/34/56
EX-10.2
from 10-Q 3 pages Background
12/34/56
EX-10.1
from 10-Q 2 pages Regenxbio Inc. Compensation Program for Non-Employee Directors
12/34/56
EX-10.23
from 10-K 3 pages Certain Identified Information Has Been Excluded From This Exhibit Pursuant to Item 601(b)(10)(iv) of Regulation S-K Because Such Information Both (I) Is Not Material and (II) Would Likely Cause Competitive Harm if Publicly Disclosed. Excluded Information Is Indicated With Brackets and Asterisks. First Amendment to License Agreement
12/34/56
EX-10.11
from 10-K 2 pages Regenxbio Inc. Compensation Program for Non-Employee Directors
12/34/56
EX-10.1
from 10-Q 34 pages Second Amendment to Lease Agreement
12/34/56
EX-10.1
from 10-Q ~1 page Regenxbio Inc. Compensation Program for Non-Employee Directors
12/34/56